Slingshot Insights

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

IMMU

100%

Additional Information

Additional Relevant Details Both abstracts are on sacituzumab govitecan, or IMMU-132, the Company’s lead antibody-drug conjugate (ADC). Sacituzumab govitecan has previously been designated by the FDA a Breakthrough Therapy for the treatment of patients with triple-negative breast cancer (TNBC) who have failed prior therapies for metastatic disease. The first abstract is a Late-Breaking Abstract on updated results from a Phase 2 study of the ADC in patients with metastatic TNBC. This abstract has also been selected as part of the Best of ASCO Program, which features the top abstracts from this year’s ASCO Annual Meeting for their practice changing research. Results in patients with metastatic non-small-cell lung cancer will be updated in another Clinical Science Symposium Session that focuses on lung cancers. In addition to these two oral presentations, a poster presentation of results with sacituzumab govitecan in patients with metastatic small-cell lung cancer will also be given

http://www.immunomed...

Additional Relevant Details Immunomedics Provides Update on Triple-Negative Breast Cancer Presentation At ASCO

http://www.immunomed...

Catalyst

Do you think this event is important to the companies below? How will it affect their stock price?

Additional Information

Slingshot Insights Explained